The goal of this observational, retrospective, non interventional study is to learn about the efficacy of an Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer (TNBC).
The main question it aims to answer is :
\- What is the efficacy of this kind of treatment, by evaluating the pathological complete response (PCR), that is to say, the percentage of patients where no tumor cells remained when they underwent surgery after neoadjuvant treatment.
The other points that will be evaluated are:
* The treatment regimen * The epidemiological characteristics of the treated population * The efficacy by relapse-free survival ; overall survival * The tolerability and adverse effects
The standard treatment for localized TNBC (larger than 2 cm or with lymph node involvement) is neoadjuvant chemoimmunotherapy, which includes anthracyclines. However, in real-world practice, some patients have a contrindication to this treatment because they have received it previously, are too old, or have comorbidities, particularly cardiovascular disease. Currently, there is limited data on the modalities and efficacy of such treatment.
Patients over 18 years of age
Patients being treated for localized triple-negative breast cancer, who received neoadjuvant chemotherapy with immunotherapy, without anthracycline
Patients who have undergone surgery, with an available pathology report.
Patient refusal to allow data use
Patient who has not undergone surgery
Metastatic patients
Patients who have received at least one anthracycline-based treatment cycle
Patients with early Triple-Negative Breast Cancer treated with an anthracycline-Free Neoadjuvant Chemoimmunotherapy
Cohort
Retrospective
Non interventional study
Other interventionNon interventional Study
Pathological Complete Response (PCR)
Adverse Effects
Epidemiologic description of the population treated
Type of treatment anthracycline-free
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
